NewsNEJMSunday, October 5, 2025 · October 5, 2025
New Oral Treatment for Fabry Disease Shows Promise
WHY IT MATTERS
Could shift Fabry treatment from hospital infusions to home-based oral therapy.
A novel oral substrate reduction therapy met its Phase 3 primary endpoint for Fabry disease.
Related conditions
Related news
FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…